Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict who benefits from dust mite allergy treatment

NCT ID NCT07436208

Knowledge-focused Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested whether two substances in the blood (sST2 and miR-223) can help predict how well patients with dust mite allergies respond to a six-month course of under-the-tongue immunotherapy (SLIT). Fifty-four patients with moderate-to-severe allergic rhinitis received daily SLIT drops. Researchers measured symptom scores and blood markers before and after treatment to see if changes in sST2 and miR-223 levels matched clinical improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sublingual immunotherapy (SLIT) containing house dust mite extracts
What this could lead to
If successful, this could lead to a simple blood test to predict which patients will benefit from SLIT for dust mite allergies.
What could go wrong
This is a small, early-phase study focused on biomarkers, not treatment effectiveness. The results may not apply to broader populations or lead to a clinical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

54 people

The number who actually took part.

Started

Feb 2025

Finished

Nov 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible participants were 14 years or older with a diagnosis of HDM-induced AR * Patients were required to have persistent moderate to severe symptoms for at least two years Exclusion Criteria: * The presence of autoimmune or chronic inflammatory conditions, severe asthma or other pulmonary disease, systemic corticosteroid or immunosuppressive therapy within four weeks prior to enrollment * Pregnancy * lactation * Refusal to provide informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HDM-induced allergic rhinitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic rhinitis perennial allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HDM-induced allergic rhinitis

Contacts and locations

Locations

  • Zagazig University outpatients clinics

    Zagazig, Egypt